Welcome to our dedicated page for Cronos Group news (Ticker: CRON), a resource for investors and traders seeking the latest updates and insights on Cronos Group stock.
Cronos Group Inc. (CRON) generates frequent news as a cannabinoid-focused company active in medical and adult-use cannabis markets across Canada, Israel and multiple international regions. Company updates often highlight brand performance, international expansion, product launches and financial results, offering investors and industry observers insight into how Cronos executes its global cannabis strategy.
News coverage for Cronos commonly includes quarterly earnings releases, where the company reports net revenue, gross profit, adjusted EBITDA and commentary on business performance by geography and brand. These releases also describe developments such as the consolidation and expansion of cultivation operations at Cronos Growing Company Inc. (Cronos GrowCo) and the company’s cash and short-term investment position.
Another major category of Cronos news involves brand and product announcements. Recent press releases describe new SOURZ by Spinach® Fully Blasted multipack gummies, seasonal Spinach® Caramel Green Apple gummies and vapes, and Lord Jones® Live Resin Fusions™ pre-rolls in Canada. These updates show how Cronos uses its Spinach® and Lord Jones® brands to introduce new formats and flavor profiles in the Canadian adult-use market.
Cronos also issues news on its international footprint and strategic transactions. Examples include the expansion of PEACE NATURALS® medical cannabis distribution in Switzerland through a partnership with Dascoli Pharma AG, and a definitive agreement for a Cronos subsidiary to acquire CanAdelaar B.V., a licensed producer in the Netherlands’ adult-use cannabis pilot program. In addition, the company has announced a junior secured convertible loan investment in High Tide Inc., a cannabis retailer, outlining the terms of that financing.
Investors and followers of CRON can use this news feed to review earnings announcements, track new product introductions under Spinach®, PEACE NATURALS® and Lord Jones®, and monitor strategic moves such as international partnerships, acquisitions and capital investments.
Cronos Group Inc. (NASDAQ: CRON) will host its 2021 Fourth Quarter and Full-Year Earnings Conference Call on March 1, 2022, at 8:30 a.m. ET. Management will discuss financial results and answer questions from investors. The call will be accessible via a live audio webcast on the company's website, with an archived version available for later listening. Cronos Group is focused on advancing cannabinoid research and technology while aiming to build a prominent brand portfolio, including Spinach®, PEACE NATURALS®, and Lord Jones®.
Cronos Group reported a significant 80% increase in consolidated net revenue for Q3 2021, totaling $20.4 million, driven by growth in Canada and the Israeli market. The company announced strategic realignment to enhance business efficiency and focus on innovation. However, it also recorded an impairment charge of $236.1 million affecting goodwill and long-lived assets. Despite the positive revenue growth, adjusted EBITDA worsened to $(46.8) million, indicating ongoing financial challenges. The company is committed to improving internal controls and expanding its product portfolio.
Cronos Group Inc. (NASDAQ: CRON) will host its 2021 Third Quarter Earnings Conference Call on February 18, 2022, at 8:30 a.m. EST. The call will cover the company’s financial results and include a Q&A session. A live audio webcast will be accessible on the company's website, and an archived version will also be available. Cronos Group, a leading cannabinoid company, focuses on building a disruptive intellectual property portfolio and an iconic brand lineup that includes PEACE NATURALS®, COVE™, Spinach®, Lord Jones®, Happy Dance®, and PEACE+™.
Cronos Group (NASDAQ: CRON) has issued a default status report as per NP 12-203 guidelines, following the announcement of a management cease trade order (MCTO) on November 9, 2021. The MCTO restricts trading by the CEO and CFO until the filing of the overdue Quarterly Report on Form 10-Q for Q3 2021, expected by February 18, 2022. However, the company confirms no material changes have occurred since the original announcement. Cronos Group remains committed to adhering to NP 12-203 guidelines while in default.
Cronos Group Inc. (NASDAQ: CRON) issued a default status report in compliance with NP 12-203, acknowledging a management cease trade order (MCTO) due to delays in filing its Quarterly Report for Q3 2021. Initially announced on November 9, 2021, the company has until February 18, 2022, to meet filing deadlines. The MCTO restricts trading for the CEO and CFO but not other shareholders. Cronos assures that no new material issues have arisen since the original announcement and commits to continue adhering to NP 12-203 guidelines until compliance is achieved.
Cronos Group (NASDAQ: CRON) has issued a default status report following its application for a management cease trade order (MCTO) due to an inability to file its Quarterly Report on Form 10-Q for the period ending September 30, 2021, by the deadline. The MCTO, effective November 16, 2021, restricts trading by executives until necessary filings are made. Cronos anticipates filing by January 31, 2022, and reports no new material developments since the original announcement. The company is committed to compliance with alternative information guidelines while in default.
Cronos Group Inc. (NASDAQ: CRON) provides a default status report in compliance with NP 12-203 due to a management cease trade order (MCTO) stemming from its inability to file the Quarterly Report on Form 10-Q for Q3 2021 on time. The MCTO, issued on November 16, 2021, restricts trading by the CEO and CFO until the Required Filings are completed. The company aims to submit these filings by January 31, 2022, though this is not guaranteed. Cronos confirms no other significant changes since its initial announcement and will continue to comply with NP 12-203 guidelines.
Cronos Group Inc. (NASDAQ: CRON) has issued a default status report under NP 12-203 due to its inability to file the Quarterly Report on Form 10-Q for the period ending September 30, 2021, by the deadline. Following the announcement on November 9, 2021, a management cease trade order (MCTO) was issued on November 16, 2021, restricting trades by the CEO and CFO. The company is working to meet the filing deadline, now expected by January 31, 2022, and confirms that there have been no material changes since the original announcement.
NatuEra has launched the Holiday Chill Bundle, a collection of five CBD wellness products aimed at alleviating holiday stress. The bundle features tinctures, capsules, and gummies, all containing Lemon Balm and varying levels of CBD sourced from sustainably grown hemp in Colombia's Andes Mountains. Priced at $99.99, the bundle offers a 23% discount compared to individual purchases and includes free shipping. NatuEra's products are manufactured in GMP-certified facilities, ensuring high quality and compliance with U.S. standards.
Aurora Cannabis (ACB) and 22nd Century Group (XXII) announced a licensing agreement with Cronos Group (CRON) to advance cannabinoid biosynthesis research. This non-exclusive deal aims to enhance the production of rare cannabinoids such as CBG, CBC, and CBN efficiently and with high purity. According to CEO Miguel Martin, the collaboration is a significant step towards commercializing cannabinoid products, which could benefit health and wellness applications. Aurora and 22nd Century also plan to enforce their intellectual property rights against infringements.